Always one step ahead

Not every company can draw upon more than 100 years of experience. Seqirus was created in 2015 when our parent company, CSL Limited, acquired the Novartis Influenza Vaccine business. Both companies had been leaders for decades in developing and producing influenza vaccines. In fact, CSL plays an important role as far back as the Spanish Flu pandemic of 1918.

Today we are the second largest influenza company in the world, and a major partner in the control of influenza globally. Our footprint empowers us to do big things - and it also creates a wealth of career opportunities on five different continents for our people. Our innovative approach to developing and producing influenza vaccines has made us a major supplier in both Northern and Southern Hemisphere markets and a transcontinental partner in pandemic preparedness and response. In Australia and New Zealand, we are the leading provider of in-license vaccines and pharmaceuticals. We are also the world's only manufacturer of Q fever vaccine and Australian-specific antivenoms, which we produce in the national interest.

Seqirus operates state-of-the-art production facilities in the US, UK and Australia, and manufactures influenza vaccines using both egg-based and cell-based technologies. We have R&D labs around the world and commercial operations in more than 30 countries.

Our impact is global


See for yourself

To learn more about Seqirus' history and our plans for the future, watch the short video The Seqirus Story: 100 Years and Just Getting Started.